Inhaled therapies for NTM disease – The way forward?

Despite improvements in the control of respiratory infections and life expectancy in cystic fibrosis (CF), highly resistant pathogens such as nontuberculous mycobacteria have emerged as an increasing challenge [1]. Disease due to M. abscessus is of particular concern as it is associated with increased healthcare utilisation, accelerated lung function decline, impaired quality of life (QoL) [2], adverse impacts on post-lung transplant outcomes [3], and increased mortality [2]. Good quality evidence to support current treatment regimens is lacking, and access to effective antimicrobial treatment options is limited.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Editorial Source Type: research